Metallopharmaceutical

Last updated
Carboplatin, an example of a metallopharmaceutical Carboplatin-2D-skeletal.png
Carboplatin, an example of a metallopharmaceutical

A metallopharmaceutical is a drug that contains a metal as an active ingredient. [1] [2] Most commonly metallopharmaceuticals are used as anticancer or antimicrobial agents. The efficiency of metallopharmaceuticals is crucially dependent on the respective trace metal binding forms. [3]

Examples of metallopharmaceuticals include:

Related Research Articles

<span class="mw-page-title-main">Medical uses of silver</span>

The medical uses of silver include its use in wound dressings, creams, and as an antibiotic coating on medical devices. Wound dressings containing silver sulfadiazine or silver nanomaterials may be used to treat external infections. The limited evidence available shows that silver coatings on endotracheal breathing tubes may reduce the incidence of ventilator-associated pneumonia. There is tentative evidence that using silver-alloy indwelling catheters for short-term catheterizing will reduce the risk of catheter-acquired urinary tract infections.

<i>Helicobacter pylori</i> Species of bacteria

Helicobacter pylori, previously known as Campylobacter pylori, is a gram-negative, flagellated, helical bacterium. Mutants can have a rod or curved rod shape, and are less effective. Its helical body is thought to have evolved in order to penetrate the mucous lining of the stomach, helped by its flagella, and thereby establish infection. The bacterium was first identified as the causal agent of gastric ulcers in 1983 by the Australian doctors Barry Marshall and Robin Warren.

<i>Helicobacter</i> Genus of bacteria

Helicobacter is a genus of gram-negative bacteria possessing a characteristic helical shape. They were initially considered to be members of the genus Campylobacter, but in 1989, Goodwin et al. published sufficient reasons to justify the new genus name Helicobacter. The genus Helicobacter contains about 35 species.

<span class="mw-page-title-main">Methotrexate</span> Chemotherapy and immunosuppressant medication

Methotrexate (MTX), formerly known as amethopterin, is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma. Types of autoimmune diseases it is used for include psoriasis, rheumatoid arthritis, and Crohn's disease. It can be given by mouth or by injection.

<span class="mw-page-title-main">Carboplatin</span> Medication used to treat cancer

Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.

<span class="mw-page-title-main">Cisplatin</span> Pharmaceutical drug

Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. It is given by injection into a vein.

<span class="mw-page-title-main">Ionophore</span> Chemical entity that reversibly binds ions

In chemistry, an ionophore is a chemical species that reversibly binds ions. Many ionophores are lipid-soluble entities that transport ions across the cell membrane. Ionophores catalyze ion transport across hydrophobic membranes, such as liquid polymeric membranes or lipid bilayers found in the living cells or synthetic vesicles (liposomes). Structurally, an ionophore contains a hydrophilic center and a hydrophobic portion that interacts with the membrane.

<span class="mw-page-title-main">Penicillamine</span> Chemical compound

Penicillamine, sold under the brand name of Cuprimine among others, is a medication primarily used for the treatment of Wilson's disease. It is also used for people with kidney stones who have high urine cystine levels, rheumatoid arthritis, and various heavy metal poisonings. It is taken by mouth.

<span class="mw-page-title-main">Furazolidone</span> Chemical compound

Furazolidone is a nitrofuran antibacterial agent and monoamine oxidase inhibitor (MAOI). It is marketed by Roberts Laboratories under the brand name Furoxone and by GlaxoSmithKline as Dependal-M.

<span class="mw-page-title-main">MALT lymphoma</span> Medical condition

MALT lymphoma is a form of lymphoma involving the mucosa-associated lymphoid tissue (MALT), frequently of the stomach, but virtually any mucosal site can be affected. It is a cancer originating from B cells in the marginal zone of the MALT, and is also called extranodal marginal zone B cell lymphoma.

<span class="mw-page-title-main">Gold-containing drugs</span> Ionic chemical compounds of the element

Gold-containing drugs are pharmaceuticals that contain gold. Sometimes these species are referred to as "gold salts". "Chrysotherapy" and "aurotherapy" are the applications of gold compounds to medicine. Research on the medicinal effects of gold began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis. The use of gold compounds has decreased since the 1980s because of numerous side effects and monitoring requirements, limited efficacy, and very slow onset of action. Most chemical compounds of gold, including some of the drugs discussed below, are not salts, but are examples of metal thiolate complexes.

<span class="mw-page-title-main">Gastric lymphoma</span> Medical condition

Primary gastric lymphoma is an uncommon condition, accounting for less than 15% of gastric malignancies and about 2% of all lymphomas. However, the stomach is a very common extranodal site for lymphomas. It is also the most common source of lymphomas in the gastrointestinal tract.

<span class="mw-page-title-main">Auranofin</span> Chemical compound

Auranofin is a gold salt classified by the World Health Organization as an antirheumatic agent. It has the brand name Ridaura.

Triplatin tetranitrate is a platinum-based cytotoxic drug that underwent clinical trials for the treatment of human cancer. The drug acts by forming adducts with cellular DNA, preventing DNA transcription and replication, thereby inducing apoptosis. Other platinum-containing anticancer drugs include cisplatin, carboplatin, and oxaliplatin.

<span class="mw-page-title-main">Satraplatin</span> Chemical compound

Satraplatin is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.

<span class="mw-page-title-main">Hydrazine sulfate</span> Chemical compound

Hydrazine sulfate, more properly hydrazinium hydrogensulfate, is a salt of the cation hydrazinium and the anion bisulfate (hydrogensulfate), with the formula N2H6SO4 or more properly [N2H5]+[HSO4]. It is a white, water-soluble solid at room temperature.

The respiratory tract antimicrobial defense system is a layered defense mechanism which relies on components of both the innate and adaptive immune systems to protect the lungs and the rest of the respiratory tract against inhaled microorganisms.

Platinum-based antineoplastic drugs are chemotherapeutic agents used to treat cancer. Their active moieties are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, commonly used drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development. Addition of platinum-based chemotherapy drugs to chemoradiation in women with early cervical cancer seems to improve survival and reduce risk of recurrence.

Ruthenium anti-cancer drugs are coordination complexes of ruthenium complexes that have anticancer properties. They promise to provide alternatives to platinum-based drugs for anticancer therapy. No ruthenium anti-cancer drug has been commercialized.

<span class="mw-page-title-main">Lobaplatin</span> Chemical compound

Lobaplatin is a platinum-based antineoplastic metallodrug approved exclusively in China for the treatment of small cell lung cancer, inoperable metastatic breast cancer and chronic myelogenous leukaemia. The drug is a third-generation analogue of cisplatin, the first globally approved and widely used platinum-based anticancer drug.

References

  1. Guo J, Sadler PJ (1999). Medicinal Inorganic Chemistry. Advances in Inorganic Chemistry. Vol. 49. pp. 183–306. doi:10.1016/S0898-8838(08)60271-8. ISBN   9780120236497.{{cite book}}: |journal= ignored (help)
  2. Ray S, Mohan R, Singh JK, Samantaray MK, Shaikh MM, Panda D, Ghosh P (December 2007). "Anticancer and antimicrobial metallopharmaceutical agents based on palladium, gold, and silver N-heterocyclic carbene complexes". J. Am. Chem. Soc. 129 (48): 15042–53. doi:10.1021/ja075889z. PMID   17988129.
  3. Günther K, Weber G (1999). "Elementspeziesanalytik: Ein Überblick". Analytiker-Taschenbuch. Vol. 20. pp. 71–103. doi:10.1007/978-3-642-59914-9_3. ISBN   978-3-642-64181-7.
  4. Fischbach L, Evans EL (August 2007). "Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori". Aliment. Pharmacol. Ther. 26 (3): 343–57. doi:10.1111/j.1365-2036.2007.03386.x. PMID   17635369. S2CID   20973127.
  5. Graham DY, Shiotani A (June 2008). "New concepts of resistance in the treatment of Helicobacter pylori infections". Nat. Clin. Pract. Gastroenterol. Hepatol. 5 (6): 321–31. doi:10.1038/ncpgasthep1138. PMC   2841357 . PMID   18446147.
  6. Lokich J, Anderson N (January 1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature". Ann. Oncol. 9 (1): 13–21. doi: 10.1023/A:1008215213739 . PMID   9541678.
  7. Go RS, Adjei AA (January 1999). "Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin". J. Clin. Oncol. 17 (1): 409–22. doi:10.1200/JCO.1999.17.1.409. PMID   10458260.
  8. Messori L, Marcon G (2004). "Gold complexes in the treatment of rheumatoid arthritis". Met. Ions Biol. Syst. 41: 279–304. PMID   15206120.
  9. Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM, Scholte-Voshaar M, van Riel P, Gossec L (June 2010). "Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis". Ann. Rheum. Dis. 69 (6): 1004–9. doi:10.1136/ard.2009.127225. PMID   20447954. S2CID   30886393.
  10. Fuller FW (2009). "The side effects of silver sulfadiazine". J. Burn Care Res. 30 (3): 464–70. doi:10.1097/BCR.0b013e3181a28c9b. PMID   19349889. S2CID   3676574.
  11. Carter MJ, Tingley-Kelley K, Warriner RA (October 2010). "Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: a systematic review and meta-analysis". J. Am. Acad. Dermatol. 63 (4): 668–79. doi:10.1016/j.jaad.2009.09.007. PMID   20471135.
  12. Guthery E, Seal LA, Anderson EL (February 2005). "Zinc pyrithione in alcohol-based products for skin antisepsis: persistence of antimicrobial effects". Am J Infect Control. 33 (1): 15–22. doi:10.1016/j.ajic.2004.07.012. PMC   7119132 . PMID   15685130.

Further reading